Sinopharm Group Co Ltd
HKEX:1099

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
HKEX:1099
Watchlist
Price: 19.98 HKD -0.84% Market Closed
Market Cap: 62.4B HKD
Have any thoughts about
Sinopharm Group Co Ltd?
Write Note

Sinopharm Group Co Ltd
Treasury Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sinopharm Group Co Ltd
Treasury Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Treasury Stock CAGR 3Y CAGR 5Y CAGR 10Y
Sinopharm Group Co Ltd
HKEX:1099
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Treasury Stock
-ÂĄ457.4m
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
N/A
C
China National Medicines Corp Ltd
SSE:600511
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Huadong Medicine Co Ltd
SZSE:000963
Treasury Stock
-ÂĄ82.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Accord Medicines Corp Ltd
SZSE:000028
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sinopharm Group Co Ltd
Glance View

Market Cap
62.4B HKD
Industry
Health Care

Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.

Intrinsic Value
78.18 HKD
Undervaluation 74%
Intrinsic Value
Price

See Also

Back to Top